Literature DB >> 24517644

The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Stephen P H Alexander1, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Michael Spedding, John A Peters, Anthony J Harmar.   

Abstract

The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full. G protein-coupled receptors are one of the seven major pharmacological targets into which the Guide is divided, with the others being G protein-coupled receptors, ligand-gated ion channels, ion channels, catalytic receptors, nuclear hormone receptors, transporters and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. A new landscape format has easy to use tables comparing related targets. It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in previous Guides to Receptors and Channels. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and the Guide to Receptors and Channels, providing a permanent, citable, point-in-time record that will survive database updates.
Copyright © 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24517644      PMCID: PMC3892287          DOI: 10.1111/bph.12445

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  2034 in total

1.  Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors.

Authors:  Yasushi Masuda; Yoshihiro Takatsu; Yasuko Terao; Satoshi Kumano; Yoshihiro Ishibashi; Masato Suenaga; Michiko Abe; Shoji Fukusumi; Takuya Watanabe; Yasushi Shintani; Takao Yamada; Shuji Hinuma; Nobuhiro Inatomi; Tetsuya Ohtaki; Haruo Onda; Masahiko Fujino
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

2.  Potency and selectivity of the tachykinin NK3 receptor antagonist SR 142801.

Authors:  J C Beaujouan; M Saffroy; Y Torrens; J Glowinski
Journal:  Eur J Pharmacol       Date:  1997-01-29       Impact factor: 4.432

3.  Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.

Authors:  R Guerrini; G Calo; A Rizzi; C Bianchi; L H Lazarus; S Salvadori; P A Temussi; D Regoli
Journal:  J Med Chem       Date:  1997-06-06       Impact factor: 7.446

4.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

5.  Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.

Authors:  H M Sarau; R S Ames; J Chambers; C Ellis; N Elshourbagy; J J Foley; D B Schmidt; R M Muccitelli; O Jenkins; P R Murdock; N C Herrity; W Halsey; G Sathe; A I Muir; P Nuthulaganti; G M Dytko; P T Buckley; S Wilson; D J Bergsma; D W Hay
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

6.  Ligand cross-reactivity within the protease-activated receptor family.

Authors:  B D Blackhart; K Emilsson; D Nguyen; W Teng; A J Martelli; S Nystedt; J Sundelin; R M Scarborough
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

7.  Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Authors:  N Vita; F Oury-Donat; P Chalon; M Guillemot; M Kaghad; A Bachy; O Thurneyssen; S Garcia; C Poinot-Chazel; P Casellas; P Keane; G Le Fur; J P Maffrand; P Soubrie; D Caput; P Ferrara
Journal:  Eur J Pharmacol       Date:  1998-11-06       Impact factor: 4.432

8.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

9.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

10.  Essential structural motif in the C-terminus of the PACAP type I receptor for signal transduction and internalization.

Authors:  J R Pisegna; R M Lyu; P M Germano
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

View more
  448 in total

1.  The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

Authors:  Maria Grazia Cascio; Erica Zamberletti; Pietro Marini; Daniela Parolaro; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

Review 2.  Histamine H₄ receptors in the gastrointestinal tract.

Authors:  A Deiteren; J G De Man; P A Pelckmans; B Y De Winter
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 3.  Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China.

Authors:  Z W Pan; Y J Lu; B F Yang
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

4.  Identification of muscarinic receptor subtypes involved in catecholamine secretion in adrenal medullary chromaffin cells by genetic deletion.

Authors:  Keita Harada; Hidetada Matsuoka; Hironori Miyata; Minoru Matsui; Masumi Inoue
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

5.  Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice.

Authors:  Molly S Crowe; Emma Leishman; Matthew L Banks; Ramesh Gujjar; Anu Mahadevan; Heather B Bradshaw; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

6.  Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5).

Authors:  A Steen; A H Sparre-Ulrich; S Thiele; D Guo; T M Frimurer; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 7.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

8.  Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.

Authors:  J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

9.  NPY/Y₁ receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.

Authors:  S Crnkovic; B Egemnazarov; P Jain; U Seay; N Gattinger; L M Marsh; Z Bálint; G Kovacs; B Ghanim; W Klepetko; R T Schermuly; N Weissmann; A Olschewski; G Kwapiszewska
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.

Authors:  M S Grace; T Lieu; B Darby; F C Abogadie; N Veldhuis; N W Bunnett; P McIntyre
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.